Description
Made available in DSpace on 2018-11-26T22:40:49Z (GMT). No. of bitstreams: 0 Previous issue date: 2018-08-01. Added 1 bitstream(s) on 2019-10-09T18:27:56Z : No. of bitstreams: 1 S0004-282X2018000800539.pdf: 336862 bytes, checksum: 861f2018734ed5dc938f69878cf50b6e (MD5)
Biogen Idec
Genzyme
Merck
Novartis
Rocha
Teva
Roche
Sanofi-Genzyme
World Federation of Neurology
European Committee on Treatment and Research in Multiple Sclerosis
Biogen
Schering
Biogen Indec
Merck-Serono
Teva (EMOCEMP Study-NCT)
Euroimmun AG
Shire
Quest/Athena Diagnostics
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Bayer
Partners MS Center, Harvard Medical School
Distrito Federal Research Foundation (FAP-DF)
Libbs
Sanofi
Serono
Teva Pharmaceuticals
Sonofi-Genzyme
Novartis-PPD
Merck Serono
Bayer Health Care
Ipsen
Sanofi Genzyme
The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.
Univ Sao Paulo, Fac Med Ribeirao Preto, Hosp Clin Ribeirao Preto, Ribeirao Preto, SP, Brazil
Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil
Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil
Univ Fed Minas Gerais, Ctr Invest Esclerose Multipla Minas Gerais, Belo Horizonte, MG, Brazil
Univ Jose Rosario Vellano, Belo Horizonte, MG, Brazil
Univ Fed Estado Rio de Janeiro, Rio De Janeiro, RJ, Brazil
Hosp Restauracao, Recife, PE, Brazil
Clin Goncalves Dias, Curitiba, Parana, Brazil
Univ Estadual Campinas, Campinas, SP, Brazil
Clin Privada, Cuiaba, MT, Brazil
Hosp Sao Rafael, Salvador, BA, Brazil
Univ Fed Fluminense, Niteroi, RJ, Brazil
Fundacac Ctr Integrado Apoio Portador Deficiencia, Joao Pessoa, Paraiba, Brazil
Univ Brasilia, Brasilia, DF, Brazil
Univ Catolica Brasilia, Brasilia, DF, Brazil
Santa Casa Misericordia Londrina, Londrina, PR, Brazil
Univ Fed Goias, Fac Med, Goiania, Go, Brazil
Clin Neurol & Endocrinol, Brasilia, DF, Brazil
Univ Estadual Paulista, Sao Paulo, SP, Brazil
Inst Neurol Curitiba, Curitiba, Parana, Brazil
Univ Regiao Joinville, Joinville, SC, Brazil
Univ Fed Amazonas, Hosp Univ Getulio Vargas, Manaus, Amazonas, Brazil
Pontificia Univ Catolica Sao Paulo, Sorocaba, SP, Brazil
Senne Liquor Diagnost, Sao Paulo, SP, Brazil
Hosp Cruz Azul, Sao Paulo, SP, Brazil
Fac Sao Leopoldo Mandic, Campinas, SP, Brazil
Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
Univ Fed Uberlandia, Uberlandia, MG, Brazil
Hosp Base Dist Fed, Brasilia, DF, Brazil
Imperial Hosp Caridade, Florianopolis, SC, Brazil
Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil
Univ Estadual Paulista, Sao Paulo, SP, Brazil
Teva (EMOCEMP Study-NCT): 61080516.4.1001.5336
